Lung Cancer Trials Ask AI to find trials
WithdrawnNot applicableNCT03443908
Official study title

Early Diagnosis and Treatment of Sleep Disordered Breathing in Lung Cancer

Study summary

Sleep-disordered breathing at night is a common medical problem. It leads to daytime fatigue, impairment in concentration and daily activities, and a higher risk of cardiovascular disease and life-threatening events. A particularly common form is obstructive sleep apnea (OSA), and it is usually treatable with a high rate of patient satisfaction and improved quality of life using a continuous positive airway pressure (CPAP) device. Treatment of this condition improves nighttime low-oxygen levels by ensuring patency of the upper airways. Research shows that in cancer, sleep disordered breathing is frequent. Low oxygen levels overnight may cause tumors to grow: tumors deprived of oxygen grow more blood vessels to try to get more oxygen, and growing more blood vessels makes the tumor grow. This study aims to examine how treating sleep-disordered breathing may lessen blood-flow to lung tumors, and thus serve to ultimately block tumor growth. Participants of this study will undergo sleep study and receive CPAP therapy as a part of routine care.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedCPAP

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 17, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Mark M. Fuster, MD

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Mark M. Fuster, MD
Interventions being studied
Device: CPAP
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Study topics
Survivorship and quality of life→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Diagnosis of lung cancer in one of 2 sub-types: 1. newly diagnosed early-stage tumor 2. advanced-stage lung tumor undergoing serial contrast-CT imaging according to standard of care
  • Diagnosis of a metastatic carcinomatous mass in the lung
  • Positive study for sleep-disordered breathing (SDB) with intermittent hypoxia (IH) and clinical recommendation for CPAP
  • Ability and willingness to undergo baseline and repeat perfusion-CT imaging following 3- to 4 weeks of CPAP therapy for SDB (regardless of CPAP compliance). Note: Participants will undergo sleep study and receive CPAP therapy as a part of routine care.
Reasons someone may not be able to joinExclusion criteria
  • Lung cancer with a negative sleep study (i.e., no SDB)
  • History of radio-contrast allergy
  • At excessive risk for contrast nephropathy (following standard radiology renal-risk criteria)
  • Pregnancy

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • UC San Diego Moores Cancer CenterLa Jolla, California

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 17, 2021. Always confirm current availability with the study team.

View original record ↗